Inhibitory potential of chlormadinone acetate (CMA) on five important UDP-glucuronosyltransferases in human liver

Pharmazie

Volumn 66, Issue 3, 2011, Pages 212-215

  Huang, Ting ^a   Fang, Zhong Ze ^b,c   Zhang, Yan Yan ^b,c   Zhu, Liang Liang ^b,c   Feng, Ling Lin ^a   Zheng, Wei ^a   Cao, Yun Feng ^d   Sun, Dong Xue ^d   Yang, Ling ^b  

^a SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; GLUCURONOSYLTRANSFERASE; ISOENZYME; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; KINETICS;

CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, HORMONAL; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KINETICS; LIVER; SUBSTRATE SPECIFICITY;

EID: 79957472949     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0745     Document Type: Article

References (21)

1. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 41-57. (Pubitemid 30055093)
2. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA (2001) The role of hepatic and extrahepatic. UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33: 273-297.
3. Herber R, Magdalou J, Haumont M, Bidault R, van Es H, Siest G (1992) Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim Biophys Acta 1139: 20-24.
4. Kiang TKL, Ensom MHH, Chang TKH (2005) UDP-Glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132. (Pubitemid 40386722)
5. Knights KM, Bowalgaha K, Miners JO (2010) Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18β-glucuronidation: A potential drug interaction. Drug Metab Disp 36: 1056-1062.
6. Lertora JJL, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, Agrawal KC (1994) Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 56: 272-278. (Pubitemid 24323918)
7. Mano Y, Usui T, Kamimura H (2007) Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol 63: 211-216. (Pubitemid 46147064)
8. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G (1998) Methadone effects on zidovudine disposition. J Acquir Defic Syndr Hum Retrovirol 18: 435-443.
9. Michalets EL (1998) Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18: 84-112.
10. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44: 1-25. (Pubitemid 38268090)
11. Miners JO, Mackenzie PI, Knights KM (2010) The prediction of drug glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42: 189-201.
12. Resetar A, Minick D, Spector T (1991) Glucuronidation of 3′-azido- 3′- deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Biochem Pharmacol 42: 559-568.
13. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321: 137-147. (Pubitemid 46456976)
14. Sahai J, Gallicano K, Pakuts A, Cameron DW (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 169: 1103-1107. (Pubitemid 24303236)
15. Tanaka E (1998) Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23: 403-416.
16. Terouanne B, Paris F, Servant N, Georget V, Sultan C (2002) Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol 198: 143-147. (Pubitemid 36169944)
17. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40: 581-616. (Pubitemid 30340694)
18. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Disp 32: 413-423. (Pubitemid 38420275)
19. i/AUC) ratios. Drug Metab Disp 32: 1201-1208.
20. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N (2001) Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203: 38-44. (Pubitemid 32830529)
21. Zahradnik HP, Goldberg J, Andreas JO (1998) Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57: 103-109. (Pubitemid 28208481)